FDA Recognition Of Orphan Drug Exclusivity, Period

No definition available.

Name:	jazz_FDARecognitionOfOrphanDrugExclusivityPeriod
Namespace Prefix:	jazz_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

FDA Stay Of Approval Period

+ References

No definition available.

+ Details

Name:	jazz_FDAStayOfApprovalPeriod
Namespace Prefix:	jazz_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Infringed Patents Suit, Number Of Patents

+ References

No definition available.

+ Details

Name:	jazz_InfringedPatentsSuitNumberOfPatents
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Patents, Paragraph IV Certification Notice Filed

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPatentsParagraphIVCertificationNoticeFiled
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_LitigationCaseAxis=jazz_LupinLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=jazz_XywavMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=jazz_TevaLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=jazz_DefitelioPatentLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=jazz_TrisPharmaPatentLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=jazz_GeneralCompositionAndMethodOfUseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=jazz_XyremMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=jazz_XywavAndXyremMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=jazz_MethodsOfTreatmentWhenAdministeredWithOtherMedicationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details)					1 Months Ended
Commitments and Contingencies (Details)	Feb. 20, 2026 patent	Apr. 16, 2025	Feb. 15, 2023 litigationCase	Jun. 22, 2022 litigationCase	Mar. 31, 2026 patent	Aug. 31, 2025 patent	Jul. 31, 2025 patent	Mar. 31, 2023 patent	Feb. 28, 2023 patent	Jul. 31, 2021 patent	Jun. 30, 2021 patent	Jan. 31, 2026 patent	Nov. 30, 2022 patent
Lupin Lawsuit
Loss Contingencies [Line Items]
Number of patents, paragraph IV certification notice filed											10
Infringed patents suit, number of patents										10			2
FDA stay of approval period (in months)										30 months
Number of lawsuits filed \| litigationCase			2	2
Lupin Lawsuit \| Xywav
Loss Contingencies [Line Items]
FDA recognition of orphan drug exclusivity, period (in years)											7 years
Teva Lawsuit
Loss Contingencies [Line Items]
Infringed patents suit, number of patents								13
FDA stay of approval period (in months)						30 months		30 months
Infringed patents suit, number of patents						14	14		13
Defitelio Patent Litigation
Loss Contingencies [Line Items]
FDA stay of approval period (in months)		30 months
Infringed patents suit, number of patents					2
Tris Pharma Patent Litigation
Loss Contingencies [Line Items]
FDA stay of approval period (in months)		30 months
Infringed patents suit, number of patents	2
Tris Pharma Patent Litigation \| Xywav
Loss Contingencies [Line Items]
Number of patents, paragraph IV certification notice filed												15
Tris Pharma Patent Litigation \| Xywav \| General Composition and Method of Use
Loss Contingencies [Line Items]
Number of patents, paragraph IV certification notice filed												8
Tris Pharma Patent Litigation \| Xyrem
Loss Contingencies [Line Items]
Number of patents, paragraph IV certification notice filed												7
Tris Pharma Patent Litigation \| Xywav and Xyrem \| Methods of Treatment when Administered with other Medications
Loss Contingencies [Line Items]
Number of patents, paragraph IV certification notice filed												7